Company intelligence / Profile preview

Sensimed

Lausanne, Vaud, Switzerlandsensimed.ch ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Sensimed’s Triggerfish® system is the first smart contact lens to provide automated, continuous 24-hour monitoring of ocular dimensional changes related to intraocular pressure. It is CE-marked, FDA-approved, and registered with Japan’s PMDA. Clinical studies have demonstrated its utility for personalized glaucoma management by enabling detection of IOP fluctuations that are missed by standard tonometry. The company is building a global registry to analyze patient data and improve treatment personalization.

Therapeutic areas: Ophthalmology
Modalities: DeviceDigital health platform
Industry: Physiological Monitoring

Drug pipeline

1 asset

SENSIMED Triggerfish

Commercial

Indications: Glaucoma

Partnerships

SEED Co., Ltd.

Beyond the preview

Go deeper on Sensimed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensimed.

Explore the full profile